biodefense News
Most Popular biodefense Story
Avant, Celldex merge in $115M stock deal
Avant Immunotherapeutics is merging with Celldex Therapeutics in a stock deal valued at $115 million. Celldex shareholders will wind up with a majority of the shares in the merged company, which will Read more...
Latest Headlines
- October 13, 2011
- August 31, 2010
- August 20, 2010
- October 22, 2007
- January 21, 2007
- January 8, 2007
- January 8, 2007
- December 20, 2006
- October 4, 2006
- September 27, 2006
- September 27, 2006
- August 14, 2006
- July 20, 2006
- June 19, 2006
- June 8, 2006
- April 9, 2006
- March 13, 2006
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
